Featuring pharma taking the lead on sharing clinical trial results, where preprints end up, and the identity of peer reviewers.
Featuring the release of the Foundations for Open Scholarship Strategy Development document, the addition of citation data to Altmetric, the launch of Participation Reports by Crossref, and The Francis Crick Institute’s commitment to open access and preprints.
Featuring the launch of cloud-based technology that enables one-click access to research articles, the new supplement for publishing negative results, and the first publisher-owned open research platform.
Open access publishing of medical research is increasingly prevalent, but open access terminology is varied and confusing. Gold, green, bronze, hybrid, CC BY, CC BY-NC – what does it all mean, and what is the best type of open access? At the 14th Annual Meeting of the International Society of Medical Publication Professionals, a panel of stakeholders in medical publications met to discuss open access from different perspectives.
At this year’s ISMPP European meeting, a panel of Open Pharma members discussed open access, preprints and post-publication peer review, and the possibility of utilizing these tools to make the publishing of pharmaceutical research faster and more transparent.
Here’s our summary of key points from selected presentations at the 2018 European meeting of ISMPP.
We aimed to gain insight into the publishing industry’s perspective on new innovations in the field, as their collaboration will be key to implementing changes.
Featuring the whodunit on the demise of Beall’s list, The Royal Society’s ORCID mandate and how authors and reviewers have responded to PeerJ’s optional open peer review. Who killed Beall's list? via The Chronicle of Higher Education A review of the prime suspects in the demise of Beall’s list, and a discussion on where open … Continue reading Weekly digest: the latest news on topics important to Open Pharma
Summary report from the Open Pharma workstream meetings in July
Open access publishing is on the rise, providing both opportunities and challenges for publishers, academics, funding bodies and pharma. However, academic authors collaborating with pharma prefer to publish in journals with the highest impact factor possible, and open access is not necessarily the authors’ priority. In our Open Pharma workstreams, we have identified a strong … Continue reading Open access education: time for a new approach?